Global Cancer Drug Market 2010-2014

Increase in the prevalence of cancer worldwide is contributing majorly to the growth of this market. The Global Cancer Drug market in the Americas, and the EMEA and APAC region has been witnessing increasing use of a combination of therapies for cancer treatment. However, presence of alternative cancer treatments such as radiation therapy and surgery could pose a challenge to the growth of this market.

This report has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the worldwide Cancer Drug market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Cancer Drug Market Report

Published: February 2012
No. of Pages: 30
Price: Single User License: US$1500 Corporate User License: US$2500






Key questions answered in this report:

• What will the market size be in 2014 and at what rate will it grow?
• What key trends is this market subject to?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the opportunities and threats faced by each of these key vendors?
• What are the strengths and weaknesses of each of these key vendors?

Table of Contents:
01. Executive Summary
02. Introduction
03. Market Coverage
04. Market Landscape
05. Vendor Landscape
06. Buying Criteria
07. Market Growth Drivers
08. Drivers and their Impact
09. Market Challenges
10. Market Trends
11. Key Vendor Analysis
11.1 Roche Pharmaceuticals Inc.
11.2 AstraZeneca Plc.
11.3 Novartis International AG
11.4 Eli Lilly and Co.
12. Other Reports in this Series

List of Exhibits:
Exhibit 1: Global Cancer Drug Market 2010-2014 (US$ billion)
Exhibit 2: Global Cancer Drug Market by Geographical Segmentation 2010
Exhibit 3: Global Cancer Drug Market by Vendor Segmentation 2010